Sirolimus is under clinical development by AI Therapeutics and currently in Phase II for Pulmonary Arterial Hypertension. According to GlobalData, Phase II drugs for Pulmonary Arterial Hypertension have a 61% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sirolimus’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sirolimus is under development for the treatment of bronchiolitis obliterans post lung transplant, tuberous sclerosis complex and pulmonary sarcoidosis. The drug candidate is administered through inhalational route. It targets mammalian target of rapamycin (mTOR). It is being developed artificial intelligence based Guardian Angel Platform.
The drug candidate was under development for the treatment of lymphangioleiomyomatosis (LAM) and pulmonary arterial hypertension.
AI Therapeutics overview
AI Therapeutics is a biopharmaceutical company that identifies and develops treatments for neurological disease and cancers. It investigating LAM-001 program against pulmonary sarcoidosis and bronchiolitis obliterans disease caused after lung transplantation resulting in obstruction of the smallest airways of the lungs. The company is also evaluating AIT–101 drug to treat amyotrophic lateral sclerosis and AIT-102 for rare diseases. AI Therapeutics is headquartered in Guilford, Connecticut, the US.
For a complete picture of Sirolimus’s drug-specific PTSR and LoA scores, buy the report here.